MedTrace Logo

Sunscreen Efficacy Against the Reccurence of Lesions Post-sun Exposure in Acneic Subjects

NCT05168397 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2021-12-23

No results posted yet for this study

Summary

The aim of this study is firstly to assess the tolerance of the sunscreen RV4857A-CD2110 after 28 days and 57 days of at least a twice daily on the study areas, secondly to assess anti-imperfection efficacy after 28 days and 57 days of use and its efficacy against recurrence of acne lesions post-sun exposure.

Conditions

Interventions

OTHER

RV4857A

RV4857A formula CD2110 is a sunscreen product

Sponsors & Collaborators

  • Pierre Fabre Dermo Cosmetique

    lead INDUSTRY

Principal Investigators

  • Pedro Contreiras Pinto, PhD · PhD Trials®

  • Leonor Girão, MD · PhD Trials®

Eligibility

Min Age
12 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-07-16
Primary Completion
2020-11-09
Completion
2020-11-09

Countries

  • Portugal

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05168397 on ClinicalTrials.gov